Home
Argenx

Argenx Market Share Analysis for August 2026

reaching patients through immunology innovation

Health > Biotechnology and Pharmaceuticals

Domainargenx.com

Year Founded2008

Employees1001 - 5000

Annual Revenue$500M - $1B

Argenx

Argenx (including company regionals)

argenx.com

See more website traffic and engagement information

Argenx Revenue up to August 2026 is 500M - 1B

revenue generated by Argenx top domains

Argenx top domains revenue over 3 years

Revenue for Argenx top domains

argenx.com500M - 1B

See more with Sales Intelligence

Total visits to Argenx's top domains

Understand Argenx market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

argenx.com93.2K

See more with Sales Intelligence

Avg. visit duration in Argenx's top domains

Analyze Argenx engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

argenx.com00:00:49

See more with Sales Intelligence

Avg. pageviews on Argenx's top domains

See how Argenx keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

argenx.com2.00

See more with Sales Intelligence

Argenx top competitors by domain

Top similar sites in August 2026, ranked by their affinity

immunovant.comCompany NameImmunovantEmployees201 - 500HQUnited States, New York, New York CityAnnual revenue$5M - $10MTotal visits5.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Argenx

These are the website technologies, by industry, used by Argenx top domains

Advertising (7)

DoubleClick

Content Management System (4)

Drupal

Social (4)

Instagram

Widget (4)

reCAPTCHA

More Technologies

12

See all

News & Signals from Argenx

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBenchSci partnered with Argenx on Sep 2nd '26.Scientist-led competitive selection deepens BenchSci's presence in European biopharma TORONTO - BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization.

NewsArgenx has valuation of $64.7B.The market capitalization climbed to 55.4 billion euros - putting Argenx ahead of Moderna again.

NewsArgenx had revenue of $1.54B on Jul 21st '26.argenex had a return on equity of 43.59% and a net margin of 32.19%.The firm had revenue of $1.54 billion for the quarter, compared to analysts' expectations of $1.45 billion.